FP-01.1-Adjuvant

BIOLOGICAL2 trials

Sponsors

Immune Targeting Systems Ltd

Conditions

Influenza A

Phase 1

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

CompletedNCT01677676

Immune Targeting Systems LtdInfluenza A

Start: 2012-01-31End: 2012-09-30Updated: 2013-07-29

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

CompletedNCT01701752

Immune Targeting Systems LtdInfluenza A

Start: 2012-09-30End: 2013-04-30Updated: 2013-07-29